title: [The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].
abstract: OBJECTIVE
  To explore the efficacy and safety of HAA regimen (homoharringtonine, cytarabine and aclarubicin) in the treatment of 150 newly diagnosed adult acute myeloid leukemia (AML).
  
  
  METHODS
  All patients entered the study from May 1999 to June 2008 were treated with HAA regimen. Cox-survival analysis was used to estimate the survival rate and differences between M(1)/M(2) and M(4)/M(5) were compared with 2-sided log-rank test.
  
  
  RESULTS
  Out of the 150 patients, 121 (81%) achieved complete remission (CR). After the first course, CR rate was 68%. The CR rates of 97%, 84% and 38% were achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. For the patients with CR, the median follow-up time was 16.5 (1.5 - 100.5) months, and the estimated 3-year survival rate was 45%. The estimated 3-year relapse free survival rate was 52% for the 121 patients with CR.
  
  
  CONCLUSIONS
  HAA regimen may be an efficacious and safe regimen with a good toleration in the induction therapy for newly diagnosed AML, and a high CR rate could be achieved with only one or two courses.
authors.affiliation: Department of Hematology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Song
authors.forename: Yin
authors.initials: Y
authors.lastname: Tong
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Qian
authors.forename: Wen-yuan
authors.initials: WY
authors.lastname: Mai
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Meng
authors.forename: Ji-jing
authors.initials: JJ
authors.lastname: Qian
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Tong
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Mao
authors.forename: Wei-lai
authors.initials: WL
authors.lastname: Xu
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage; D000077863:Homoharringtonine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006248:Harringtonines; D003561:Cytarabine; D000077863:Homoharringtonine; D015250:Aclarubicin